Patents by Inventor Frank L. Graham

Frank L. Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7189561
    Abstract: Methods, cells and recombinant adenoviral vectors are disclosed that permit the production of recombinant adenoviral vector stocks with reduced levels of contamination by replication competent adenoviruses (RCA). In certain embodiments are disclosed early region 1 (E1) deficient recombinant adenoviral vectors and complementing E1 positive host cells whose sequences are designed to avoid formation of RCA by homologous recombination between sequences in the vector and E1 sequences in the cells. One aspect of the invention involves the inversion of the packaging signal in a recombinant adenoviral vector relative to an adjacent or nearby inverted terminal repeat (ITR). Methods include use of site-specific intregrase family recombinases such as Cre or FLP and recombinase recognition sites such as lox sites or frt sites.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: March 13, 2007
    Assignee: AdVec, Inc.
    Inventor: Frank L. Graham
  • Patent number: 7135187
    Abstract: The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: November 14, 2006
    Assignee: AdVec, Inc.
    Inventors: Frank L. Graham, Philip Ng, Robin Parks
  • Patent number: 7132290
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof. Use of recombinases besides Cre and recombinase recognition sites besides lox sites, and use of cells other than 293 cells are also disclosed and enabled, as are kits incorporating the site-specific vector system.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: November 7, 2006
    Assignee: AdVec, Inc.
    Inventors: Frank L. Graham, Robin J. Parks, Philip Ng
  • Patent number: 7045347
    Abstract: This invention provides helper-dependent adenovirus cloning vectors and helper adenoviruses, and methods for making and Using such preparations, wherein the helper adenoviruses contain recombinase target sites that are useful in reducing the level of contamination of helper virus in helper-dependent adenovirus vector preparations.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: May 16, 2006
    Assignee: Advec, Inc.
    Inventors: Frank L. Graham, Michael A. Rudnicki, Martina Anton
  • Patent number: 7025967
    Abstract: The present invention relates novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: April 11, 2006
    Assignee: University of Saskatchewan
    Inventors: Suresh K. Mittal, Frank L. Graham, Ludvik Prevec, Lorne A. Babiuk
  • Patent number: 6974694
    Abstract: The invention claims a class of adenovirus vectors for delivering recombinases to a large number of cells of different origins, and methods for regulating the expression of a gene in transfected mammalian cells in culture and in cells of transgenic animals, comprising infecting said cells with an Ad vector encoding a recombinase whose target site is present at or adjacent to the gene, wherein the action of the recombinase regulates the expression of said gene.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: December 13, 2005
    Assignee: AdVec, Inc.
    Inventors: Frank L. Graham, Martina Anton, Silvia Bacchetti, Ping Wang, Michael A. Rudnicki, William J. Muller
  • Patent number: 6855534
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: February 15, 2005
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Publication number: 20040142470
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof. Use of recombinases besides Cre and recombinase recognition sites besides lox sites, and use of cells other than 293 cells are also disclosed and enabled, as are kits incorporating the site-specific vector system.
    Type: Application
    Filed: July 19, 2001
    Publication date: July 22, 2004
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Patent number: 6756226
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and optionally, recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: June 29, 2004
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Patent number: 6730507
    Abstract: This invention responds to a long felt need, by providing in one embodiment, a helper virus based on the Ad2 serotype for use in the Cre/loxP system for the generation of Ad vectors deleted of all Ad protein coding sequences. Using this and helper virus based on Ad5, genetically identical hdAd that differ only in the virion protein components, which are derived from the helper virus, were produced. The vectors have identical expression characteristics in vitro, regardless of the serotype, and the sequential use of hdAd of different serotypes allows for successful repeat vector administration in vivo.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: May 4, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Frank L. Graham, Robin Parks
  • Patent number: 6662838
    Abstract: A bench slide mount is provided, comprising a flat rectangular plate with roller slides connected to its sides, and two hinges connecting the plate to an L-shaped bench mount bracket. The bench slide mount has particular utility in connection with coupling tools to a workbench for operational use of the tools, with a unique capability to extend, pivot, and rotate for storing the tools below the workbench.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: December 16, 2003
    Inventor: Frank L. Graham, III
  • Publication number: 20030228280
    Abstract: The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.
    Type: Application
    Filed: January 31, 2003
    Publication date: December 11, 2003
    Inventors: Frank L. Graham, Philip Ng, Robin Parks, Silvia Bacchetti, Mauro Anglana
  • Publication number: 20030165463
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Application
    Filed: October 16, 2001
    Publication date: September 4, 2003
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Publication number: 20030100523
    Abstract: The invention claims a class of adenovirus vectors for delivering recombinases to a large number of cells of different origins, and methods for regulating the expression of a gene in transfected mammalian cells in culture and in cells of transgenic animals, comprising infecting said cells with an Ad vector encoding a recombinase whose target site is present at or adjacent to the gene, wherein the action of the recombinase regulates the expression of said gene.
    Type: Application
    Filed: October 17, 2001
    Publication date: May 29, 2003
    Inventors: Frank L. Graham, Martina Anton, Silvia Bacchetti, Ping Wang, Michael A. Rudnicki, William J. Muller
  • Patent number: 6566128
    Abstract: The present invention provides an improved helper-dependent vector system for production of high capacity adenoviral cloning vectors. The invention makes use of the DNA size packaging constraints imposed on a pIX-defective Ad virion that prevent such virions from packaging DNA larger than approximately 35 kb. This constraint can be used to develop helper viruses that do not package their DNA. In one embodiment, the invention combines this methodology with the Cre-loxP helper-dependent system to decrease the quantity of contaminating helper virus in vector preparations. In another embodiment the invention is used for vector growth.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: May 20, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Frank L. Graham, Robin Parks, Liane Chen
  • Publication number: 20020192185
    Abstract: The present invention relates novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.
    Type: Application
    Filed: January 14, 2002
    Publication date: December 19, 2002
    Inventors: Suresh K. Mittal, Frank L. Graham, Ludvik Prevec, Lorne A. Babiuk
  • Publication number: 20020168341
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and optionally, recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Application
    Filed: October 16, 2001
    Publication date: November 14, 2002
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Publication number: 20020146392
    Abstract: This invention provides helper-dependent adenovirus cloning vectors and helper adenoviruses, and methods for making and using such preparations, wherein the helper adenoviruses contain recombinase target sites that are useful in reducing the level of contamination of helper virus in helper-dependent adenovirus vector preparations.
    Type: Application
    Filed: July 13, 1999
    Publication date: October 10, 2002
    Inventors: FRANK L. GRAHAM, PHILLIP NG, ROBIN PARKS, CINDY BEAUCHAMP
  • Publication number: 20020136708
    Abstract: The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.
    Type: Application
    Filed: June 19, 2001
    Publication date: September 26, 2002
    Inventors: Frank L. Graham, Philip Ng, Robin Parks, Silvia Bacchetti, Mauro Anglana
  • Patent number: 6379943
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof. Use of recombinases besides Cre and recombinase recognition sites besides lox sites, and use of cells other than 293 cells are also disclosed and enabled, as are kits incorporating the site-specific vector system, as well as compositions and methods for using such compositions as vaccines or in gene therapeutic applications.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Frank L. Graham, Robin J. Parks, Philip Ng